Floatz logo

Balstilimab

Stage III Rectal Cancer AJCC v8

City of Hope Medical Centermonoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Stage III Rectal Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Trifluridine
Academic and Community Cancer Research United
Phase 2BB
TIPIRACIL
Academic and Community Cancer Research United
Phase 2BB
Nivolumab
Odense University Hospital
Phase 2B
Botensilimab
City of Hope Medical Center
Phase 2B
Regorafenib
M.D. Anderson Cancer Center
Phase 2B

View all 11 →

Same molecule, other indications

Balstilimab is also rated in:

colorectal adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →
Metastatic Colorectal AdenocarcinomaDormant
B
Indicative ·
62 / 100
View asset →
colorectal carcinomaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →